From STAT’s Allison DeAngelis: The drug industry’s love affair with obesity drugs has continued into 2025, though some companies have experienced heartbreak. BioAge, a startup focused on ...

Obesity trends have stayed stable in the last couple years, whereas severe obesity has trended downward, a recently published report suggested. However, the percentage of people with a healthy ...

Cantor Fitzgerald, in particular, has expressed high conviction in the obesity program, suggesting that MariTide could be worth approximately $140 per share ... on emerging trends in personalized ...

Published to medical journal The Lancet, the study analyzed obesity trends in 204 countries total. They found that the number of obese individuals spiked globally from 929 million to 2.6 billion ...

If historical trends and patterns continue, 3.8 billion adults will have overweight or obesity by 2050, corresponding to nearly 60% of the global adult population, researchers estimated.

The obesity medicine field has gained a new entrant, with AbbVie on Monday announcing it had licensed an experimental weight loss drug from a Danish company that is in a Phase 1 trial.

GUB014295, an amylin analog for obesity, is currently in Phase 1 trials. Get 5 stock picks identified before their biggest breakouts, identified by the same system that spotted Insmed, Sprouts ...